"Fluidigm and the Icahn School of Medicine at Mount Sinai Collaborate on Landmark Single-Cell Study of the Human Epigenome"
Fluidigm said today that it is collaborating with the Icahn School of Medicine at Mount Sinai as part of a project to develop epigenetic signatures that could identify exposure to weapons of mass destruction. The overall project, announced by Mount Sinai in June, is being funded by a $27.8 million contract from the US Defense Department's Defense Advanced Research Projects Agency as part of its Epigenetic Characterization and Observation (ECHO) program, which aims to develop new approaches to analyze epigenetic markers and new instrumentation that can be used in the field by operators with minimal training. “Our ultimate goal is to develop an assay that we can use to rapidly detect exposure of military troops to threatening agents in the future so that appropriate actions can be taken,” said Stuart Sealfon, MD, director of the Center for Translational Systems Biology at the Icahn School of Medicine at Mount Sinai.
— Stuart Sealfon, MD, Director, The Center for Translational Systems Biology, Professor, Neurology, Neuroscience, Pharmacological Sciences, Icahn School of Medicine at Mount Sinai